Genzyme in the UK

Company Info

Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)

Date: February 27, 2013

Oxford, UK. – Genzyme, a Sanofi company, announced today that it has received a Company Award from EURORDIS, the largest European patient organisation in the field of rare diseases. The EURORDIS Company Award recognizes the outstanding accomplishments of companies dedicated to rare diseases. Genzyme was honored for pioneering the development and delivery of therapies for rare diseases; its longstanding support of patient organizations - including EURORDIS - as well as initiatives to increase patient access to Genzyme treatments.

EURORDIS Award recipients are selected by the EURORDIS Board of Directors, based on over 100 nominations received from EURORDIS members (rare disease patient advocacy groups from across Europe), volunteers and staff, with the aim of promoting leadership and excellence for people living with rare diseases. Genzyme‟s Senior Vice President of Rare Diseases in Europe, Hilde Furberg, accepted the award yesterday during the EURORDIS Black Pearl Gala Dinner in Brussels as EURORDIS began its activities to recognize the sixth International Rare Disease Day on 28 February 2013.

“Genzyme has been partnering with patient advocacy organizations globally from our earliest days to be sure the community‟s needs and perspectives are always represented within our organization, and the contributions of these organizations remain central to Genzyme and our ability to bring therapies to patients,” said Genzyme‟s Head of Rare Diseases, Rogerio Vivaldi, MD. “As we approach Rare Disease Day, a day made possible because of EURORDIS, Genzyme wants to thank all of the patient organizations and communities who work daily to improve the lives of patients with rare diseases. Their pioneering spirit will continue to inspire Genzyme.”

Yann Le Cam, Chief Executive Officer of EURORDIS, said, "We are honored to acknowledge the commitment and achievements of this year‟s recipients of the EURORDIS Awards on the occasion of Rare Disease Day 2013. Each of this year‟s ten awardees contributes in their own unique way toward fostering the goals of cooperation embodied in this year‟s Rare Disease Day slogan: „Rare Disorders without Borders.‟ We are proud that the rare disease community is becoming a model for multi-stakeholder partnership and international collaboration as well as for solidarity and unity throughout Europe."

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme‟s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world‟s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

About Genzyme in the UK

Genzyme is a significant force in the UK biotechnology sector focused on improving the welfare of patients with rare inherited and immune diseases. First established in the UK in 1981, Genzyme employs 450 people at two sites. Genzyme Therapeutics in Oxford is the Company‟s UK commercial base marketing products for the treatment of patients with chronic debilitating diseases. These include genetic illnesses such as lysosomal storage disorders (LSDs) – characterised by a lack of enzymes essential to healthy biological processes. Our portfolio also includes a therapy which aids in the management of thyroid cancer.

Genzyme‟s manufacturing facility in Haverhill in Suffolk has undergone a dramatic building programme since its purchase in 1982 and now employs 350 people at a site with two large-scale manufacturing plants, a pilot plant, a development centre, warehouse and other associated facilities. Genzyme‟s Haverhill facility manufactures the active ingredients in Genzyme‟s therapies for patients undergoing renal dialysis and is a major global distribution centre for the company‟s products for genetic illnesses. Learn more at www.genzyme.co.uk

About the European Organisation for Rare Diseases (EURORDIS)

EURORDIS is a non-governmental patient-driven alliance of patient organisations representing 561 rare disease patient organisations in 51 countries. EURORDIS' mission is to build a strong pan-European community of patient organisations and people living with rare diseases, to be their voice at the European level.

Genzyme® is a registered trademark. All rights reserved

Highlight

  • Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

    Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: +01865 405200
Fax: +01865 774172
Email

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PU
Tel: +01440 703522
Fax: +01440 716269

'